Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06662058 · ClinicalTrials.gov registry record · NA

Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation

A NA study of Head and Neck Squamous Cell Carcinoma and Metastatic Head-and-neck Squamous-cell Carcinoma, sponsored by Emory University.

Recruiting
Registry status
NA
Development phase
118
Enrollment target
1
Study location

NCT06662058 is a NA study of Head and Neck Squamous Cell Carcinoma and Metastatic Head-and-neck Squamous-cell Carcinoma that is actively recruiting participants, run by Emory University. The registered enrollment target is 118 participants, roughly in line with the 116-participant average among 124 other Head and Neck Squamous Cell Carcinoma trials with a reported enrollment target. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06662058, a NA study of Head and Neck Squamous Cell Carcinoma and Metastatic Head-and-neck Squamous-cell Carcinoma, is actively recruiting participants, sponsored by Emory University.

RECRUITING
Registry status
NA
Development phase
118 participants
Enrollment target
1
Study location

Study Summary

This clinical trial tests the impact of offering hearing tests (audiometry) close to home and remotely on participation in monitoring for treatment-related hearing loss in patients with head and neck squamous cell cancer receiving cisplatin and/or radiation. Cisplatin, a chemotherapy often used to treat head and neck cancers, and radiation given near the ear can cause hearing loss in some patients. Hearing loss can have a major negative impact on quality of life, contributing to social isolation and frustration. Identifying hearing changes may allow treatment changes to prevent further loss. Audiometry measures hearing loss using a graphic record of the softest sounds that a person can hear at various frequencies. It is recommended patients have a hearing test before, during and after treatment to monitor for any hearing loss. This is usually done in the office and performed on the same day as other visits whenever possible, however, patients who live far away or have stage IV cancer, may have more difficulty coming back for hearing tests. Offering close to home and remote audiometry may improve monitoring for hearing loss in patients with head and neck squamous cell cancer receiving cisplatin and/or radiation.

Interventions

  • OTHER Interview
  • PROCEDURE Audiometric Test

Study Locations (1)

Georgia

  • Emory Midtown University Hospital/Winship Cancer Institute - Atlanta

Trial Details

FieldValue
Enrollment Target 118 participants
Start Date 2025-03-12
Est. Completion 2029-10-31
Phase NA

Sponsor

Emory University

1,208 total trials

What the Registry Record Tells You About NCT06662058

The ClinicalTrials.gov registry entry for NCT06662058 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 118 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 116-participant average among 124 other Head and Neck Squamous Cell Carcinoma trials with a reported enrollment target. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Head and Neck Squamous Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Interview is the first listed.

NCT06662058 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.

Frequently Asked Questions

What is clinical trial NCT06662058 about?

NCT06662058 is a clinical study titled "Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation". This clinical trial tests the impact of offering hearing tests (audiometry) close to home and remotely on participation in monitoring for treatment-related hearing loss in patients with head and neck squamous cell cancer receiving cisplatin and/or radiation. Cisplatin, a chemotherapy often used to t...

What is the current status of trial NCT06662058?

This trial is currently recruiting. It is a NA study. The enrollment target is 118 participants. The study started on 2025-03-12. Estimated completion is 2029-10-31.

What conditions does trial NCT06662058 study?

This clinical trial studies the following conditions: Head and Neck Squamous Cell Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma.

What interventions are being tested in trial NCT06662058?

The interventions under investigation include: Interview (OTHER), Audiometric Test (PROCEDURE).

Who is sponsoring clinical trial NCT06662058?

This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06662058 being conducted?

This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Head and Neck Squamous Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.